{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:40:24Z","timestamp":1768315224436,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Croatian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.tracli.2021.04.004","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T01:12:39Z","timestamp":1619226759000},"page":"264-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?"],"prefix":"10.1016","volume":"28","author":[{"given":"D.","family":"Rnjak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ravli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-M.","family":"\u0160ola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Halassy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"\u0160emni\u010dki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"\u0160uperba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"He\u0107imovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.-C.","family":"Kurolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kurtovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017d.","family":"Ma\u010dak \u0160afranko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Polan\u010dec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Bendelja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Mu\u0161lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Juki\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Vuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Zeni\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Artukovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2021.04.004_bib0195","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1038\/s41586-020-2202-3","article-title":"Author correction: a new coronavirus associated with human respiratory disease in China","volume":"580","author":"Wu","year":"2020","journal-title":"Nature [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0200","unstructured":"Coronavirus Disease 2019 (COVID19) Treatment Guidlines. National Instututes of Health. Available at https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed 28.02.2021. Coronavirus Disease 2019 (COVID19) Treatment Guidlines. National Instututes of Health. Available at https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed.[28.02.2021.]."},{"key":"10.1016\/j.tracli.2021.04.004_bib0205","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.jaip.2020.08.059","article-title":"Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma","volume":"8","author":"Jin","year":"2020","journal-title":"J Allergy Clin Immunol In practice [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0210","unstructured":"Velkury (remdesivir) EUA Letter of Approval. FDA O 2020. No Title [Internet]. Available from: https:\/\/www.fda.gov\/media\/137564\/download."},{"key":"10.1016\/j.tracli.2021.04.004_bib0215","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jca.21806","article-title":"Convalescent plasma therapy in patients with COVID-19","volume":"35","author":"Yi\u011feno\u011flu","year":"2020","journal-title":"J Clin Apher Journal [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0220","doi-asserted-by":"crossref","first-page":"102790","DOI":"10.1016\/j.transci.2020.102790","article-title":"Treatment for emerging viruses: Convalescent plasma and COVID-19","volume":"59","author":"Brown","year":"2020","journal-title":"Transfus Apher Sci [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0225","series-title":"A look-back at convalescent plasma to treat COVID-19","first-page":"19","author":"Garraud","year":"2020"},{"key":"10.1016\/j.tracli.2021.04.004_bib0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2015.12.003","article-title":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow","volume":"23","author":"Garraud","year":"2016","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tracli.2021.04.004_bib0235","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/cts.12816","article-title":"Active therapy with passive immunotherapy may be effective in the fight against COVID-19","volume":"13","author":"Morabito","year":"2020","journal-title":"Clin Translational Sci [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0240","article-title":"Convalescent plasma in Covid-19: possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun Rev [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0245","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-0716-0211-9_9","article-title":"Evaluation of MERS-CoV neutralizing antibodies in sera using live virus microneutralization assay","volume":"2099","author":"Algaissi","year":"2020","journal-title":"Methods Mol Biol [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0250","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/eji.202048723","article-title":"Convalescent plasma treatment for COVID-19: tempering expectations with the influenza experience","volume":"50","author":"Subbarao","year":"2020","journal-title":"Eur J Immunol [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0255","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell\u2013depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0260","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","article-title":"Prolonged severe acute respiratory syndrome Coronavirus 2 replication in an immunocompromised patient","volume":"223","author":"Baang","year":"2021","journal-title":"J Infect Dis [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0270","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.xcrm.2020.100164","article-title":"Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency","volume":"2","author":"Honjo","year":"2021","journal-title":"Cell Reports Medicine [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0275","first-page":"1","article-title":"Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies","author":"Ferrari","year":"2021","journal-title":"Leuk Lymphoma [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12659\/AJCR.927812","article-title":"A 63-year-old woman with a history of nonhodgkin lymphoma with persistent sars-cov-2 infection who was seronegative and treated with convalescent plasma","volume":"21","author":"Moore","year":"2020","journal-title":"Am J Case Reports"},{"key":"10.1016\/j.tracli.2021.04.004_bib0285","first-page":"8571","article-title":"Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients","volume":"9","author":"Tremblay","year":"2020","journal-title":"C Med"},{"key":"10.1016\/j.tracli.2021.04.004_bib0290","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s10875-020-00904-5","article-title":"Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy","volume":"41","author":"London","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.tracli.2021.04.004_bib0295","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.tracli.2021.04.004_bib0300","doi-asserted-by":"crossref","first-page":"112957","DOI":"10.1016\/j.jim.2021.112957","article-title":"Impact of complement and difference of cell-based assay and ELISA in determination of neutralization capacity against mumps and measles virus","volume":"490","author":"Brgles","year":"2021","journal-title":"J Immunol Methods [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0305","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1080\/21645515.2015.1062191","article-title":"Factors influencing preclinical in vivo evaluation of mumps vaccine strain immunogenicity","volume":"11","author":"Halassy","year":"2015","journal-title":"Hum vaccin immunotherapeutics [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0310","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2047-1440-2-17","article-title":"Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study","volume":"2","author":"Streitz","year":"2013","journal-title":"Transplantation research [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0315","doi-asserted-by":"crossref","DOI":"10.1002\/cyto.a.24314","article-title":"CD169 and CD64 could help differentiate bacterial from CoVID-19 or other viral infections in the Emergency Department","author":"Bourgoin","year":"2021","journal-title":"Cytometry Part A"},{"key":"10.1016\/j.tracli.2021.04.004_bib0320","unstructured":"Guidelines for COVID-19 treatment. Croatian Ministry of health N 2020. No Title [Internet]. Available from: https:\/\/zdravlje.gov.hr\/UserDocsImages\/\/2020 CORONAVIRUS\/\/Smjernice za lije\u010denje oboljelih od koronavirusne bolesti 2019 (COVID-19), verzija 2 od 19. studenoga 2020.pdf?."},{"key":"10.1016\/j.tracli.2021.04.004_bib0325","first-page":"e154","article-title":"Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery","volume":"190","author":"Clark","year":"2020","journal-title":"Br J Haematol [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0330","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.tracli.2021.04.004_bib0335","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1172\/JCI140965","article-title":"SARS\u2013CoV-2\u2013specific T cell responses and correlations with COVID-19 patient predisposition","volume":"130","author":"Sattler","year":"2020","journal-title":"J Clin Invest [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0340","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T Cells in patients with Coronavirus Disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Frontiers in immunology [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0345","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40560-020-00453-4","article-title":"Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis","volume":"8","author":"Huang","year":"2020","journal-title":"J Intensive Care"},{"key":"10.1016\/j.tracli.2021.04.004_bib0350","first-page":"318","article-title":"Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19","volume":"81","author":"Liu","year":"2020","journal-title":"J infect [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0355","doi-asserted-by":"crossref","first-page":"119124","DOI":"10.1016\/j.lfs.2021.119124","article-title":"SARS-CoV-2 infection: The role of PD-1\/PD-L1 and CTLA-4 axis","volume":"270","author":"Aghbash","year":"2021","journal-title":"Life sciences [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0360","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.imlet.2020.06.013","article-title":"Lymphopenia during the COVID-19 infection: what it shows and what can be learned","volume":"225","author":"Tavakolpour","year":"2020","journal-title":"Immunology letters [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0365","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/cyto.a.24249","article-title":"Monocyte HLA-DR measurement by flow cytometry in COVID-19 patients: an interim review","volume":"97","author":"Benlyamani","year":"2020","journal-title":"Cytometry Part A [Internet]"},{"key":"10.1016\/j.tracli.2021.04.004_bib0370","unstructured":"Coronavirus (COVID-19) Update: February 5, 2021. FDA F 2021. (https:\/\/www. fda. gov\/news-events\/press-announcements\/coronavirus-covid-19-update-february-5-2021). No Title."},{"key":"10.1016\/j.tracli.2021.04.004_bib0375","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2021.04.004_bib0380","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2217\/imt-2020-0263","article-title":"Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma","volume":"13","author":"Ali","year":"2021","journal-title":"Immunotherapy [Internet]"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782021000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782021000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:39:23Z","timestamp":1761129563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782021000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1246782021000653"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2021.04.004","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2021.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}